Meeting
2023 ASCO Annual Meeting
MammaPrint Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2- breast cancer in NBRST.
Authors
Peter D. Beitsch
Dallas Surgical Group, Dallas, TX
Peter D. Beitsch , James V. Pellicane , Lajos Pusztai , Paul Baron , Erin Frances Cobain , Mary K. Murray , Andrew Ashikari , Pond R. Kelemen , Angela Marie Mislowsky , Julie Barone , Kenneth H. Cowan , Rakhshanda Layeequr Rahman , William C. Dooley , Andrea Menicucci , Christine Finn , M. William William Audeh , Pat W. Whitworth
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT01479101
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 521)
DOI
10.1200/JCO.2023.41.16_suppl.521
Abstract #
521
Poster Bd #
351
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Race and response to neoadjuvant chemotherapy according to MammaPrint risk.
First Author: Raquel Nunes
Poster
2024 ASCO Annual Meeting
Impact of extent of disease at presentation on oncologic outcomes according to pathologic response to neoadjuvant systemic therapy among participants of the I-SPY2 clinical trial.
First Author: Roberto Antonio Leon-Ferre
Poster
2022 ASCO Annual Meeting
Does race influence long-term outcomes after neoadjuvant chemotherapy in breast cancer: A National Cancer Database analysis.
First Author: Arya Mariam Roy
Poster
2019 Breakthrough
Image-guided vacuum-assisted biopsy to assess pathologic complete response in breast cancer patients with exceptional response to neoadjuvant chemotherapy.
First Author: Victoria Teoh